

ADVANCED
OVARIAN CANCER:
OPTIMAL THERAPY.
UPDATE

PROGRAM

Chairmen: JB Vermorken , R. Ozols, A.Poveda

Valencia 26th February 1999

09.00-10.00 GENETICS

- Molecular approaches to epithelial ovarian cancer: potential implications for therapy.
R.C. Bast (Houston, USA)

10.00-11.30 SURGERY

- Surgical staging, surgical guidelines and the importance of lymphadenectomy vs lymph node sampling in ovarian cancer.
J.B. Trimpos (Leiden, The Netherlands)
- Surgical vs chemical upfront debulking in advanced ovarian cancer.
S. Pecorelli (Brescia, Italy)
- The impact of a specialist training for surgery in ovarian cancer
E. Junor (Glasgow, Scotland)

11.30-12.00 COFFE BREAK12.00-13.30 CHEMOTHERAPY

State of the art lectures with respect to:

- Intravenous chemotherapy
S.B. Kaye (Glasgow, Scotland)
- Intraperitoneal chemotherapy
J.B. Vermorken (Antwerp, Belgium)
- Consolidation therapies
R. Ozols (Philadelphia, USA)

14.00 LUNCH15.30-17.50 FUTURE DIRECTIONS

- New cytotoxics and noncytotoxics
E.A. Eisenhauer (Kingston, Canada)
- The use of monoclonal antibodies intraperitoneally
A.A. Epenetos (London, UK)
- Strategies for resistance modulation
E.G.E. de Vries (Groningen, The Netherlands)
- Possible roles for high-dose chemotherapy with PBSCT
J.A. Ledermann (London, UK)

17.50-18.00 • Remarks and conclusions
A.Poveda (Valencia, Spain)